HAVN Life at Q1 2022 Virtual Investor Summit

CEO Tim Moore will join 80+ other small cap and micro cap companies at leading investor event

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and cognitive function, is announcing that CEO Tim Moore will be presenting at the Q1 2022 Virtual Investor Summit, taking place on March 8th & 9th. Connecting more than 80 companies with leading qualified investors, the Virtual Investor Summit is the largest independent investor conference for individuals intending to buy on the open market.

HAVN Life CEO Tim Moore will give a presentation on March 8th at 3:30pm (EST) sharing updates on the Company’s growth and activities to the investor audience. Mr. Moore will also host a Q & A session for investors following his presentation.

“I’m thrilled to be participating at the Virtual Investor Summit and look forward to sharing our recent distribution and partnership successes, as well as upcoming plans with this illustrious group of investors and other emerging companies,” says Moore. “It’s a great opportunity to educate the investor community about the market potential of the work we’re doing,” he adds.

WHO: Tim Moore, CEO of HAVN Life Sciences Inc.
WHEN: Tuesday, March 8, 2022 at 3:30 PM Eastern / 12:30 PM Pacific
WHERE: Click this link to access the HAVN Life live presentation

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding Mr. Moore’s attendance and presentation at the Virtual Investor Summit, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that Mr. Moore will not be able to attend and/or present at the Virtual Investor Summit as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Leave a Comment

Your email address will not be published.

Scroll to Top